Study Overview
OCD imposes significant burdens and has been exacerbated by the COVID-19 pandemic. This study aims to develop and validate a prevention program for at-risk adults utilizing cognitive-behavioral therapy and exposure response prevention techniques.
Methods
The study will involve a single-blind, randomized controlled trial comparing the prevention program to a waitlist control group. At-risk adults with subclinical OCD symptoms will be recruited, and the prevention program will consist of six online group sessions over three modules.
Outcomes
The primary outcomes will measure OCD symptom severity, depression and anxiety symptoms. Secondary outcomes include various psychological measures. Follow-up will be conducted to analyze the OCD diagnostic incidence using specific clinical interviews and statistical tests.
Discussion
The study aims to contribute novel data on the efficacy of OCD prevention approaches, potentially leading to the development of an evidence-based OCD prevention program.
Trial Information
The trial was approved by the University Ethical Review Authority and is registered on clinicaltrials.gov.
Clinical Trial Software Solutions
DocSym, an AI-driven platform, consolidates clinical standards and research into an easily accessible knowledge base for clinicians. Streamlining operations is crucial in today’s healthcare environment, and our mobile apps support scheduling, treatment monitoring, and telemedicine, helping clinics to enhance workflows and improve patient outcomes.
